CN102858368B - 通用病毒样颗粒(vlp)流感疫苗 - Google Patents

通用病毒样颗粒(vlp)流感疫苗 Download PDF

Info

Publication number
CN102858368B
CN102858368B CN201180019751.2A CN201180019751A CN102858368B CN 102858368 B CN102858368 B CN 102858368B CN 201180019751 A CN201180019751 A CN 201180019751A CN 102858368 B CN102858368 B CN 102858368B
Authority
CN
China
Prior art keywords
cells
influenza
vlp
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180019751.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858368A (zh
Inventor
乔斯·加拉尔萨
乔治·R·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technovax Inc
Original Assignee
Technovax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technovax Inc filed Critical Technovax Inc
Publication of CN102858368A publication Critical patent/CN102858368A/zh
Application granted granted Critical
Publication of CN102858368B publication Critical patent/CN102858368B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180019751.2A 2010-02-18 2011-02-18 通用病毒样颗粒(vlp)流感疫苗 Expired - Fee Related CN102858368B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30576810P 2010-02-18 2010-02-18
US30575910P 2010-02-18 2010-02-18
US61/305,768 2010-02-18
US61/305,759 2010-02-18
PCT/US2011/000300 WO2011102900A1 (en) 2010-02-18 2011-02-18 Universal virus-like particle (vlp) influenza vaccines

Publications (2)

Publication Number Publication Date
CN102858368A CN102858368A (zh) 2013-01-02
CN102858368B true CN102858368B (zh) 2017-04-12

Family

ID=44483229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180019751.2A Expired - Fee Related CN102858368B (zh) 2010-02-18 2011-02-18 通用病毒样颗粒(vlp)流感疫苗

Country Status (6)

Country Link
US (4) US9352031B2 (https=)
EP (1) EP2536428B1 (https=)
JP (2) JP2013520167A (https=)
CN (1) CN102858368B (https=)
CA (1) CA2789945A1 (https=)
WO (1) WO2011102900A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2789945A1 (en) * 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CN103154021A (zh) * 2010-08-16 2013-06-12 威斯特解剖及生物研究所 通用甲型流感疫苗
CA2849822C (en) * 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
AU2012315421C1 (en) * 2011-09-30 2019-12-05 Aramis Biotechnologies Inc. Increasing virus-like particle yield in plants
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
US9364530B2 (en) 2012-03-22 2016-06-14 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN112592389A (zh) 2013-03-28 2021-04-02 莫迪卡戈公司 植物中流感样病毒颗粒的产生
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
EP3733244A1 (en) * 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
US10744199B2 (en) 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
EP3157557A1 (en) * 2014-06-20 2017-04-26 The U.S.A. as represented by the Secretary, Department of Health and Human Services Polyvalent influenza virus-like particles (vlps) and use as vaccines
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
SG11201901790YA (en) 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
CN110272473B (zh) * 2019-07-10 2021-03-02 军事科学院军事医学研究院军事兽医研究所 甲型流感通用型病毒样颗粒及其制备方法和应用
US20230321219A1 (en) * 2020-08-17 2023-10-12 Technovax, Inc. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES
AU2021342576A1 (en) * 2020-09-21 2023-04-06 University Of Georgia Research Foundation, Inc. PIV5-based covid-19 vaccine
CN112342149A (zh) * 2020-11-12 2021-02-09 新疆畜牧科学院兽医研究所（新疆畜牧科学院动物临床医学研究中心） 一种禽流感病毒样颗粒组装表达系统及其应用
AU2022425707A1 (en) * 2021-12-31 2024-07-04 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof
CN120053630B (zh) * 2025-04-28 2025-07-18 中国医学科学院医学生物学研究所 一种广谱流感疫苗的抗原表位肽组合及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849134A (zh) * 2003-07-11 2006-10-18 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(VLPs)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5008244B2 (ja) * 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
JP5714799B2 (ja) * 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
US8815252B2 (en) * 2008-11-25 2014-08-26 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CA2789945A1 (en) * 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
KR102072582B1 (ko) * 2012-12-31 2020-02-03 엘지전자 주식회사 듀얼 디스플레이 방법 및 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849134A (zh) * 2003-07-11 2006-10-18 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(VLPs)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.;Bright RA et.al;《PLoS One》;20080131;1-14 *
Influenza Virus-Like Particles as Pandemic Vaccines;S.M.Kang et.al;《Current topics in microbiology and immunology》;20090101;269-289 *
Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.;R J Webby et.al;《Lancet》;20041231;1099-1103 *

Also Published As

Publication number Publication date
US20160303223A1 (en) 2016-10-20
US10695418B2 (en) 2020-06-30
EP2536428A4 (en) 2014-04-09
EP2536428A1 (en) 2012-12-26
US9352031B2 (en) 2016-05-31
CN102858368A (zh) 2013-01-02
JP2016198107A (ja) 2016-12-01
US10080796B2 (en) 2018-09-25
US11529410B2 (en) 2022-12-20
US20110212128A1 (en) 2011-09-01
CA2789945A1 (en) 2011-08-25
US20200297836A1 (en) 2020-09-24
US20190091323A1 (en) 2019-03-28
EP2536428B1 (en) 2018-12-05
JP2013520167A (ja) 2013-06-06
WO2011102900A1 (en) 2011-08-25
JP6524555B2 (ja) 2019-06-05

Similar Documents

Publication Publication Date Title
US11529410B2 (en) Universal virus-like particle (VLP) influenza vaccines
US9387241B2 (en) Influenza virus-like particle (VLP) compositions
US9101578B2 (en) Polyvalent influenza virus-like particle (VLP) compositions
US20110097358A1 (en) RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
JP6643239B2 (ja) 免疫原性の中東呼吸器症候群コロナウイルス（ＭＥＲＳ−ＣｏＶ）組成物および方法
AU2004249133B2 (en) High titer recombinant influenza viruses for vaccines and gene therapy
US9884105B2 (en) Production of viral vaccine
CN114929269A (zh) 用于疫苗开发的改进的流感病毒复制
KR101835989B1 (ko) 인플루엔자 바이러스의 다중 아형 h3 및 h7 에 대한 다중 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
US10098944B2 (en) Recombinant swine influenza virus and uses thereof
NZ620275B2 (en) Recombinant swine influenza virus and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170412